What can happen when people stop taking GLP-1 medications
The increase in appetite for obesity drugs
A simpler workflow with less exposure to bottlenecks: Fewer impurities mean fewer byproducts to wash out, which cuts down on cycle time and potentially clears the way for less intensive downstream purificationall while improving overall yield
doi: 10.2146/ajhp050459 48 SimonsenLHolstJJDeaconCF
Ultimately, however, advocates for GLP-1s (both patients and pharmaceutical companies) want to see full Medicare coverage
Zhang Y, Zhang Q, Bai Y, Zheng H, Ji L, Zhu X et al (2023) Glycogen synthesis kinase-3 involves in the analgesic effect of liraglutide on diabetic neuropathic pain